🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
- This event has passed.
April 20 @ 10:00 am - 10:45 am
Join ATMA and MAPS trained therapist and educator, Mike Mathers, for an information and Q&A session on MDMA-assisted therapy for PTSD. With Oregon and Colorado dominating the news of psychedelic therapy focusing on psilocybin, there are a lot of misconception that all psychedelic therapies are similar. The truth is that MDMA and psilocybin therapy are significantly different in the therapy process.
According to MAPS, MDMA therapy may likely be more accessible to North Americans sooner than psilocybin as MAPS has completed their clinical trial Phase 3B and in application to MDMA to be designated as a therapy drug.
Wherever you practice in North America, if you are interested in MDMA assisted therapy and are wanting to understand more about it, you will benefit from the information and discussion on this subject.